C12N5/0695

Delta133P53Beta and Delta133P53Gamma Isoforms Are Biomarkers of Cancer Stem Cells
20170355964 · 2017-12-14 ·

The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of Δ133ρ536 isoform, Δ133ρ53γ isoform, or both Δ133ρ536 and Δ133ρ53γ isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in Δ133ρ536 isoform, Δ133ρ53γ isoform, or both Δ133ρ536 and Δ133ρ53γ isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing Δ133p536 isoform, Δ133ρ53γ isoform, or both Δ133ρ536 and Δ133ρ53γ isoforms expression; and also to screening methods for anti-cancer stem cells agents.

CULTURE MEDIUM FOR EXPANDING BREAST EPITHELIAL STEM CELLS

The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids.

BINDING PROTEINS SPECIFIC FOR LOX1 AND USES THEREOF

This disclosure provides LOX1 (LOX1) binding proteins such as anti-LOX1 antibodies, and compositions and methods for making these binding proteins. In certain aspects the LOX1-binding proteins provided herein, inhibit, or antagonize LOX1 activity. In addition, the disclosure provides compositions and methods for diagnosing and treating conditions associated with atherosclerosis, thrombosis, coronary artery disease (CAD), ischemia (e.g., myocardial ischemia), infarction (e.g., myocardial infarction), acute coronary syndrome (ACS), stroke, reperfusion injury, restenosis, peripheral vascular disease, hypertension, heart failure, inflammation (e.g., chronic inflammation), angiogenesis, preeclampsia, cancer and other LOX1-mediated diseases and conditions.

Method for isolating cancer stem cells

The invention relates to the use of a lectin that recognizes the fucose α 1-2 galactose unit, as a first means for labeling and optionally a second means for labelling colorectal cancer stem cells, in particular a lectin that recognizes the T antigen, in order to carry out a method for the detection and optionally isolation of colorectal cancer stem cells, a method for the detection and optionally isolation of colorectal cancer stem cells for research purposes, and a method for the in vitro diagnosis of colorectal cancer recurrence risk and/or aggressiveness so as to define a prognostic value in order to make colorectal cancer therapy adjustments, as well as a kit comprising a lectin that recognizes the fucose α 1-2 galactose unit and a lectin that recognizes the T antigen.

CULTURE MEDIUM

The invention relates to improved culture methods for expanding epithelial stem cells and obtaining organoids, to culture media involved in said methods, and to uses of said organoids.

Bioreactor System
20220033769 · 2022-02-03 ·

A three dimensional cell culture and bioreactor system is provided. The system comprises one or more cell culture chamber. Each cell culture chamber comprises an inlet port and an outlet port in fluid communication with the cell culture chamber. The cell culture chambers may be segregated or in fluid communication with one another. The systems may be used to conduct drug efficacy test, isolate certain cell types from a complex tissue sample of multiple cell types, allow for the ex vivo culturing of patient tissue samples to help guide the course of treatment, and conduct co-culture experiments.

CULTURE MEDIUM AND METHOD FOR ENRICHING AND MAINTAINING CANCER STEM CELLS (CSCS) USING SAID MEDIUM

The present invention relates to a serum-free conditioned medium that solves the drawbacks mentioned in the prior art, as it does not require prior handling of the cells, and it furthermore allows starting from a large population with no additional cost. This medium favors in vitro proliferation and conservation of the pluripotency potential that allows maintaining a state that is undifferentiated with respect to the subpopulation of cancer stem cells (CSCs) and in turn does not allow survival of the differentiated cells.

Fluorescent Synthetic Retinoids
20170217893 · 2017-08-03 · ·

There are described novel compounds of formula I: which R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 and R.sup.10 are each as herein defined.

##STR00001##

Multi-Well Plate and Method for Preparing Same
20220235303 · 2022-07-28 ·

The invention relates to a multi-well plate comprising a support, the upper surface of which is at least partially covered with a continuous layer of a hydrogel in contact with the lower surface of a bottomless multi-well plate, the support, the continuous layer, and the bottomless multi-well plate being adhered by means of an adhesive which extends from at least certain portions of the lower surface of the bottomless multi-well plate up to certain portions of the upper surface of the support by passing through the continuous layer of hydrogel, each well of the bottomless multi-well plate being entirely surrounded by the at least certain portions of the lower surface. The application also relates to a method for preparing the multi-well plate and the use thereof for in vitro cell culture.

METHODS AND MATERIALS FOR HEMATOENDOTHELIAL DIFFERENTIATION OF HUMAN PLURIPOTENT STEM CELLS UNDER DEFINED CONDITIONS
20220228118 · 2022-07-21 ·

Methods, kits and compositions for differentiating pluripotent stem cells into cells of endothelial and hematopoietic lineages are disclosed.